Earnings call transcript: HLS Therapeutics Q1 2026 shows EPS beat, revenue miss

HLS Therapeutics reported Q1 revenue of CAD 12.9 million, up 2% year over year, with EPS of CAD -0.07 beating expectations by 12.5%, though revenue missed consensus by 5.7%. Operating cash flow rose 80% to CAD 6.4 million and management reaffirmed 2026 guidance for revenue of $56 million-$60 million and adjusted EBITDA of $18.5 million-$21 million. The key growth driver is NILEMDO’s launch, which is seeing strong early demand and private payer coverage, while Vascepa sales rose 15% and net debt declined to CAD 31.9 million.

Analysis

The setup is less about the quarter and more about sequencing: HLS is effectively de-risking a launch-led re-rating while preserving cash generation from the legacy base. That matters because the company now has two short-cycle catalysts that can compound into 2027, and the market typically underprices staged launches when early payer coverage and wholesaler reorders show up before formal claims data. The bigger second-order effect is that stronger commercial execution in one asset appears to be lifting the entire salesforce’s productivity, which should improve the ROI on incremental spend and reduce the probability that launch economics become a margin trap.

The main winner here may actually be the balance sheet. With operating cash flow inflecting faster than EBITDA, HLS can absorb launch costs, continue debt paydown, and still retain optionality for buybacks or small tuck-in deals. That combination tends to support multiple expansion because it shifts the story from a single-product cash harvester to a capital compounder with embedded growth, while the downside case is now more about launch cadence than solvency or liquidity.

The market is likely missing that the real sensitivity is not near-term EPS, but payer conversion velocity over the next 2-3 quarters. If private coverage broadens as expected and prescriptions continue to rise, the street will need to move 2027 revenue assumptions meaningfully higher well before public reimbursement lands. The contrarian risk is that the launch thesis gets ahead of actual net revenue capture if access is broad but utilization lags, or if Ontario-related Clozaril normalization takes longer than management assumes; that would create a temporary valuation air pocket after the initial enthusiasm fades.

Key Decisions for Investors

• Long HLS.TO on a 3-6 month horizon: prefer entry on any post-earnings consolidation; asymmetry is favorable if launch momentum translates into prescription data and payer breadth, with downside limited by cash generation and deleveraging.
• Buy HLS.TO Jan-2027 calls or call spreads: structure around the 2027 catalyst stack; the options market should underprice the step-up if NILEMDO/NEXLETOL adoption follows even a moderate trajectory.
• Pair trade: long HLS.TO / short a basket of slower-growth Canadian healthcare cash-flow names over 3-6 months; HLS has identifiable organic catalysts while peers are more ex-growth and less levered to product launches.
• Tactical hedge: if long HLS.TO, finance with short-dated covered calls against strength into the next quarter; the risk is a sharp rerate before hard prescription data arrives, so size for gap risk.
• Watchlist trigger: add on confirmation of sustained weekly reorder trends and broader private payer wins; if those stall for 2 consecutive months, trim exposure because the launch thesis becomes much more valuation-dependent.